濮阳东方医院男科治阳痿口碑很好价格低濮阳东方医院妇科技术很靠谱,濮阳东方妇科医院口碑好价格低,濮阳东方看男科评价,濮阳东方男科医院割包皮非常好,濮阳东方医院看妇科病技术可靠,濮阳东方医院看男科病口碑比较好,濮阳东方医院男科割包皮好吗

WASHINGTON, March 24 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Thursday approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox.After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging."The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease" said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement. ( Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache, according to the FDA.Zostavax, manufactured by Merck & Co., was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.

LOS ANGELES, May 8 (Xinhua) -- Kids born in the spring and summer months might be more likely to develop celiac disease, U.S. researchers have found.Researchers from the Massachusetts General Hospital for Children drew the conclusion after examining data on 382 children diagnosed with celiac disease at between 11 months and 19 years of age, HealthDay News reported on Sunday.The study found that in the 15- to 19-year-old set, birth season appeared to make no difference, but among 317 children younger than 15 years of age, 57 percent were born in the "light" season of March through August, compared with 43 percent who were born in the "dark" season of September through February.The findings suggest that the higher incidence of this autoimmune disease may be related to a combination of seasonal and environmental factors, the report said.Celiac disease is a digestive disorder triggered by consuming the protein gluten, which is primarily found in bread and other foods containing wheat, barley or rye. It can damage the small intestine and make it difficult to absorb certain nutrients, causing problems ranging from abdominal pain to nerve damage.Even though the exact cause of celiac disease is unknown, potential triggers include the timing of infants' introduction to gluten, and viral infections contracted during the first year of life.The study's findings suggest the season of a child's birth is another potential risk factor for the disease.The researchers pointed out that infants are generally introduced to solid foods containing gluten at around six months of age, which for spring and summer babies would coincide with cold and flu season.Based on the findings, the age at which gluten is first offered to some babies may need to be altered, said the study's lead researcher, Dr. Pornthep Tanpowpong. "If you're born in the spring or the summer, it might not be appropriate to introduce gluten at the same point as someone born in the fall or winter," said Tanpowpong. "Although we need to further develop and test our hypothesis, we think it provides a helpful clue for ongoing efforts to prevent celiac disease."The study also noted that exposure to sunlight may also play a role in celiac disease, since vitamin D deficiency has been associated with the disease.The study was presented Sunday in Chicago during Digestive Disease Week, an international gathering sponsored by the American Gastroenterological Association and other organizations, HealthDay News said.Because the study was presented at a medical meeting and is small, its findings should be considered preliminary until published in a peer-reviewed journal and confirmed in other research, the report said.

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

BEIJING, Jan. 29 (Xinhua) -- Chinese State Councilor Dai Bingguo and U.S. National Security Advisor Tom Donilon on Saturday both spoke highly of Chinese President Hu Jintao's state visit to the United States earlier this month.During a phone conversation, Dai and Donilon agreed that China and the United States should make joint efforts to properly implement the consensus reached by leaders on both sides and cement the achievements made during Hu's visit, which was on Jan. 18-21.They also said that the two sides should maintain the current momentum in the development of bilateral ties and devote themselves to building a cooperative partnership based on mutual respect and mutual benefit.

BEIJING, Feb. 9 (Xinhua) -- China has introduced new stimulus policies to boost the development of the software and integrated circuit (IC) industries.Software firms will continue to enjoy preferential value-added tax policies, according to a circular posted on the central government's website, www.gov.cn on Wednesday. The circular was dated Jan. 28.The new policies also granted tax cuts to manufacturers of integrated circuit. Enterprises of IC products whose product line is less than 0.8 micron (including 0.8 micron) wide will be exempted from corporate income taxes on the first and the second year after reaching profitability, according to the statement.Taxes will also be halved for such companies from the third to fifth year after reaching profitability.Makers of IC products that have a product line that is less than 0.25 micron wide or have invested more than 8 billion yuan (1.21 billion U.S. dollars) in production will pay reduced income taxes.For companies that have operated for more than 15 years, corporate income taxes will be exempted from the first year to the fifth after reaching profitability.Between the sixth and the tenth year, the firms will pay half of the taxes, the statement said.The government also encouraged consolidation in the software and IC industries and will provide financial support to technological research and development.